Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
HUTCHMED (China) ( (HK:0013) ) has issued an announcement.
HUTCHMED (China) Limited announced that as of May 30, 2025, its issued share capital consists of 871,611,095 ordinary shares, each carrying one voting right. This information is crucial for shareholders to determine their interest in the company under the Financial Conduct Authority’s rules, and it highlights the company’s transparency and regulatory compliance in its operations.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed its first three medicines in China, with one also approved in the US, Europe, and Japan.
Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.